Foreskin fibroblast (neonatal) is a treatment of cells used to treat full-thickness, diabetic foot ulcers that extend through the dermis without tendon, muscle, joint capsule, or bone exposure. Foreskin fibroblast-like stromal cells (FDSCs) are progenitors isolated from human tissue that can differentiate into various cell types.
- Mechanism
- Curator reviewed · 2 references
Dermagraft is a cryopreserved, human fibroblast-derived dermal substitute that contains fibroblasts, extracellular matrix, and a bioabsorbable polyglactin mesh scaffold. The fibroblasts are obtained from human newborn foreskin tissue. The fibroblasts are then placed on a scaffold and progress to proliferate and produce human dermal collagen, matrix proteins, growth factors, and cytokines. The above steps create a three-dimensional human dermal substitute with active human cells. Dermagraft does not contain macrophages, lymphocytes, blood vessels, nor hair follicles. It is available frozen as a single sheet (2 by 3 inches) for a single application.
- Primary indication
- This device is indicated for use for the treatment of full-thickness, diabetic foot ulcers greater than six weeks duration which extends through the dermis, but without tendon, muscle, joint capsule or bone exposure.Curator reviewed · 1 structured indication
- First approval
- United States, 2012
- Also known as
- foreskin fibroblast, neonatal
- Brand names
Resolves to
What you can answer from here — as of April 02, 2025
Which drugs share a target with Foreskin fibroblast (neonatal), and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account